PMID- 10706856
OWN - NLM
STAT- MEDLINE
DCOM- 20000407
LR  - 20210216
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 95
IP  - 6
DP  - 2000 Mar 15
TI  - Deletion of 13q14 remains an independent adverse prognostic variable in multiple 
      myeloma despite its frequent detection by interphase fluorescence in situ 
      hybridization.
PG  - 1925-30
AB  - Interphase fluorescence in situ hybridization (FISH) studies of chromosomal 
      region 13q14 were performed to investigate the incidence and clinical importance 
      of deletions in multiple myeloma (MM). Monoallelic deletions of the 
      retinoblastoma-1 (rb-1) gene and the D13S319 locus were observed in 48 of 104 
      patients (46.2%) and in 28 of 72 (38.9%) patients, respectively, with newly 
      diagnosed MM. FISH studies found that 13q14 was deleted in all 17 patients with 
      karyotypic evidence of monosomy 13 or deletion of 13q but also in 9 of 19 
      patients with apparently normal karyotypes. Patients with a 13q14 deletion were 
      more likely to have stage III disease (P =.022), higher serum levels of 
      beta(2)-microglobulin (P =.059), and a higher percentage of bone marrow plasma 
      cells (P =.085) than patients with a normal 13q14 status on FISH analysis. In 
      patients with a deletion of 13q14, myeloma cell proliferation (Ki-67) was 
      markedly increased (22.0% +/- 6.9% compared with 15.6% +/- 8.2% in patients 
      without the deletion; P =.0008). Evaluation of bromodeoxyuridine incorporation in 
      5 patients revealed that both rb-1-deleted and rb-1-normal MM subpopulations were 
      proliferative. The presence of a 13q14 deletion on FISH analysis was associated 
      with a significantly lower rate of response to conventional-dose chemotherapy 
      (40.8% compared with 78. 6%; P =.009) and a shorter overall survival (24.2 months 
      compared with > 60 months; P <.005) than in patients without the deletion. 
      Multivariate analysis of prognostic factors confirmed the independent predictive 
      value of 13q14 deletions for shortened survival. In conclusion, deletions of 
      13q14 are frequently detected by interphase FISH in patients with newly diagnosed 
      MM, correlate with increased proliferative activity, and represent an independent 
      adverse prognostic feature in MM. (Blood. 2000;95:1925-1930)
FAU - Zojer, N
AU  - Zojer N
AD  - Department of Internal Medicine I, Division of Clinical Oncology, University of 
      Vienna, Austria.
FAU - Konigsberg, R
AU  - Konigsberg R
FAU - Ackermann, J
AU  - Ackermann J
FAU - Fritz, E
AU  - Fritz E
FAU - Dallinger, S
AU  - Dallinger S
FAU - Kromer, E
AU  - Kromer E
FAU - Kaufmann, H
AU  - Kaufmann H
FAU - Riedl, L
AU  - Riedl L
FAU - Gisslinger, H
AU  - Gisslinger H
FAU - Schreiber, S
AU  - Schreiber S
FAU - Heinz, R
AU  - Heinz R
FAU - Ludwig, H
AU  - Ludwig H
FAU - Huber, H
AU  - Huber H
FAU - Drach, J
AU  - Drach J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Interleukin-6)
RN  - 0 (RNA, Messenger)
RN  - 0 (Retinoblastoma Protein)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Chromosome Deletion
MH  - *Chromosomes, Human, Pair 13
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Interleukin-6/metabolism
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/diagnosis/*genetics/mortality
MH  - Prognosis
MH  - RNA, Messenger/metabolism
MH  - Retinoblastoma Protein/metabolism
MH  - Time Factors
EDAT- 2000/03/09 00:00
MHDA- 2000/03/09 00:01
CRDT- 2000/03/09 00:00
PHST- 2000/03/09 00:00 [pubmed]
PHST- 2000/03/09 00:01 [medline]
PHST- 2000/03/09 00:00 [entrez]
AID - S0006-4971(20)66950-6 [pii]
PST - ppublish
SO  - Blood. 2000 Mar 15;95(6):1925-30.